Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 24, 2020
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Jane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2014
18F-FDG kinetics parameters depend on the mechanism of injury in early experimental acute respiratory distress syndrome
Nicolas de Prost, Yan Feng, Tyler Wellman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 9, 2020
PET Imaging Reveals Early Pulmonary Perfusion Abnormalities in HIV Infection Similar to Smoking
Puja Kohli, Vanessa J Kelly, Kathryn A Hibbert, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
Seth Walker, Patrick Flume, John McNamara, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 28, 2019
Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at Rest
Puja Kohli, Vanessa J Kelly, Ekaterina G Kehl, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
Gregory S Sawicki, Mark Chilvers, John McNamara, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 13, 2011
18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma
R Scott Harris, José G Venegas, Chanikarn Wongviriyawong, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 5, 2021
Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure
Jehan Alladina, Sean D Levy, Josalyn L Cho, et al.
American Journal of Respiratory Cell and Molecular Biology
|
June 24, 2021
Smoking and Human Immunodeficiency Virus 1 Infection Promote Retention of CD8<sup>+</sup> T Cells in the Airway Mucosa
Björn Corleis, Josalyn L Cho, Samantha J Gates, et al.
Respiratory Research
|
December 2, 2022
Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker
Tilo Winkler, Puja Kohli, Vanessa J Kelly, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 24, 2020
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Jane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2014
18F-FDG kinetics parameters depend on the mechanism of injury in early experimental acute respiratory distress syndrome
Nicolas de Prost, Yan Feng, Tyler Wellman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 9, 2020
PET Imaging Reveals Early Pulmonary Perfusion Abnormalities in HIV Infection Similar to Smoking
Puja Kohli, Vanessa J Kelly, Kathryn A Hibbert, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
Seth Walker, Patrick Flume, John McNamara, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 28, 2019
Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at Rest
Puja Kohli, Vanessa J Kelly, Ekaterina G Kehl, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
Gregory S Sawicki, Mark Chilvers, John McNamara, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 13, 2011
18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma
R Scott Harris, José G Venegas, Chanikarn Wongviriyawong, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 5, 2021
Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure
Jehan Alladina, Sean D Levy, Josalyn L Cho, et al.
American Journal of Respiratory Cell and Molecular Biology
|
June 24, 2021
Smoking and Human Immunodeficiency Virus 1 Infection Promote Retention of CD8<sup>+</sup> T Cells in the Airway Mucosa
Björn Corleis, Josalyn L Cho, Samantha J Gates, et al.
Respiratory Research
|
December 2, 2022
Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker
Tilo Winkler, Puja Kohli, Vanessa J Kelly, et al.
Page
of 8